A systematic review of economic analyses of low-molecular-weight heparin for the treatment of venous thromboembolism

Thrombosis Research

Volumn 112, Issue 4, 2003, Pages 193-201

  Sprague, Sheila ^a   Cook, Deborah J ^a   Anderson, David ^b   O'Brien, Bernie J ^a,c  

^a MCMASTER UNIVERSITY   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

^c CENTRE FOR EVALUATION OF MEDICINES   (Canada)

Author keywords

Economic evaluation; Low molecular weight heparin; Venous thromboembolism

Indexed keywords

HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ANTICOAGULATION; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DISEASE ASSOCIATION; DRUG COST; DRUG EFFICACY; DRUG SCREENING; DRUG UTILIZATION; ECONOMIC ASPECT; HEALTH CARE COST; HOSPITAL ADMISSION; HUMAN; OUTPATIENT; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; VENOUS THROMBOEMBOLISM;

EID: 1342302814     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2003.12.001     Document Type: Review

References (82)

1. Eisenberg J.M. Clinical economics: a guide to the economic analysis of clinical practice. JAMA. 262:1989;2879-2886.
2. Detsky A.S., Nagie I.G. A clinician's guide to cost-effectiveness analysis. Ann. Intern. Med. 113:1990;147-154.
3. O'Brien B.J., Drummond M.F., Labelle R.J., Willan A. In search of power and significance: issues in the design and analysis of stochastic cost-effectiveness studies in health care. Med. Care. 32:1994;150-163.
4. Rodger M., Bredeson C., Wells P.S., Beck J., Kearns B., Huebsch L.B. Cost-effectiveness of low-molecular-weight heparin and unfractionated heparin in treatment of deep vein thrombosis. CMAJ. 159:1998;931-938.
5. Estrada C.A., Mansfield C.J., Heudebert G.R. Cost-effectiveness of low-molecular-weight heparin in the treatment of proximal deep vein thrombosis. J. Gen. Intern. Med. 15:2000;108-115.
6. Anderson D.R., O'Brien B. Cost effectiveness of the prevention and treatment of deep vein thrombosis and pulmonary embolism. PharmacoEconomics. 12(1):1997;17-29.
7. Drummond M.F., Richardson W.S., O'Brien B.J., Levine M., Heyland D. Users' Guides to the Medical Literature XII How to Use and an Article on Economic Analysis of Clinical Practice A. Are the Results of the Study Valid? JAMA. 277(19):1997;1552-1557.
8. O'Brien B.J., Heyland D., Richardson W.S., Levine M., Drummond M.F. Users' guides to the medical literature XII. How to use and an article on economic analysis of clinical practice B. Are the results and will they help me in caring for my patients? JAMA. 277(22):1997;1802-1806.
9. Caro J.J., Getsios D., Caro I., O'Brien J.A. Cost effectiveness of tinzaparin sodium versus unfractionated heparin in the treatment of proximal deep vein thrombosis. PharmacoEconomics. 20(9):2002;593-602.
10. Koopman M.M.W., Prandoni P., Piovella F., Ockelford P.A., Brandjes D.P.M., van der Meer J.et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N. Engl. J. Med. 334(11):1996;682-687.
11. De Lissovoy G., Yusen R.D., Spiro T.E., Krupski W.C., Champion A.H., Sorensen S.V. Cost for inpatient care of venous thrombosis: a trial of enoxaparin versus standard heparin. Arch. Intern. Med. 160:2000;3160-3165.
12. Hull R., Raskob G.E., Rosenbloom D., Pineo G.F., Lerner R.G., Gafni A.et al. Treatment of proximal vein thrombosis with subcutaneous low-molecular- weight heparin vs. intravenous heparin. Arch. Intern. Med. 157:1997;289-294.
13. O'Brien B., Levine M., Willan A., Goeree R., Haley S., Blackhouse G.et al. Economic evaluation of outpatient treatment with low-molecular-weight- heparin for proximal vein thrombosis. Arch. Intern. Med. 159:1999;2298-2304.
14. Gould M.K., Dembitzer A.D., Sanders G.D., Garber A.M. Low-molecular-weight heparins compared with unfractionated heparin for the treatment of acute deep vein thrombosis: a cost-effectiveness analysis. Ann. Intern. Med. 130(10):1999;789-799.
15. Lloyd A., Aitken J., Hoffmeyer U.K.O., Kelso E.J., Wakerly E.C., Barber N.D. Economic evaluation of the use of nadroparin calcium in the treatment of deep vein thrombosis in Switzerland. Ann. Pharmacother. 31:1997;842-846.
16. O'Brien J.A., Caro J.J. Direct medical cost of managing deep vein thrombosis according to theoccurrence of complications. PharmacoEconomics. 20(9):2002;603-615.
17. Lapidus L., Borretzen J., Fahlen M., Thomsen H.G., Hasselblom S., Larson L.et al. Home treatment of deep vein thrombosis. An out-patient treatment model with once-daily injection of low-molecular-weight heparin (tinzaparin) in 555 patients. Pathophysiol. Haemost. Thromb. 32(2):2002;59-66.
18. Lindmarker P., Holmstrom M. Use of low molecular weight heparin (dalteparin) once daily for the treatment of deep vein thrombosis: a feasibility and health economic study in an outpatient setting. J. Intern. Med. 240:1996;395-401.
19. Spyropoulos A.C., Hurley J.S., Ciesla G.N., de Lissovoy G. Management of acute proximal deep vein thrombosis: pharmacoeconomic evaluation of outpatient with enoxaparin vs. inpatient treatment with unfractionated heparin. Chest. 122:2002;108-114.
20. Tillman D.J., Charland S.L., Witt D.M. Effectiveness and economic impact associated with a program for outpatient management of acute deep vein thrombosis in a group model heath maintenance organization. Arch. Intern. Med. 160:2000;2926-2932.
21. Anderson D.R., O'Brien B.J., Levine M.N., Roberts R., Wells P.S., Hirsch J. Efficacy and cost of LMWH compared with standard heparin for the prevention of DVT after total hip arthroplasty. Ann. Intern. Med. 119(11):1993;1105-1112.
22. Bergqvist D., Lindgren B., Matzsch T. Comparison of the cost of preventing postoperative deep vein thrombosis with either unfractionated or low molecular weight heparin. Br. J. Surg. 83(11):1996;1548-1552.
23. Borris L.C., Lassen M.R. Thromboprophylaxis with LMWH after major orthopaedic surgery. Drugs. 52(7):1996;42-46.
24. Borris L.C., Lassen M.R., Jensen H.P., Anderson B.S., Poulsen K.A. Perioperative thrombosis prophylaxis with LMWHs in elective hip surgery. Int. J. Clin. Pharmacol. Ther. 32(5):1995;262-268.
25. Botteman M.F., Caprini J., Stephens J.M., Nadipelli V., Bell C.F., Pashos C.L.et al. Results of an economic model to assess the cost-effectiveness of enoxaparin, a low-molecular-weight heparin, versus warfarin for the prophylaxis of deep vein thrombosis and associated long-term complications in total hip replacement surgery in the United States. Clin. Ther. 24(11):2002 (Nov.);1960-1986.
26. Caprini J.A., Arcelus J., Sehgal L.R., Cohen E.B., Reyna J.J. The use of low molecular weight heparins for the prevention of postoperative venous thromboembolism in general surgery. A survey of practice in the United States. Int. Angiol. 21(1):2002 (Mar.);78-85.
27. Cohen A.T. Discoveries in thrombosis care for medical patients. Semin. Thromb. Hemost. 28(Suppl. 3):2002 (Aug.);13-17.
28. de Lissovoy G., Subedi P. Economic evaluation of enoxaparin as prophylaxis against venous thromboembolism in seriously ill medical patients: a US perspective. Am. J. Manag. Care. 8(12):2002 (Dec.);1082-1088.
29. Drummond M., Aristides M., Davies L., Forbes C. Economic evaluation of standard heparin and enoxaparin for prophylaxis against DVT in elective hip surgery. Br. J. Surg. 81:1994;1742-1746.
30. Etchells E., McLeod R., Geerts W., Barton P., Detsky A. Economic analysis of low-dose heparin vs. the LMWH enoxaparin for prevention of venous thromboembolism after colorectal surgery. Arch. Intern. Med. 159:1999;1221-1228.
31. Friedmann R.J., Dunswork G.A. Cost analyses of extended prophylaxis with enoxaparin after hip arthroplasty. Clin. Orthop. Relat. Res. 370:1999;171-182.
32. Garces K. Fondaparinux for post-operative venous thrombosis prophylaxis. Issues Emerg. Health Technol. (37):2002 (Aug.);1-4.
33. Hauch O., Khatter S.C., Jorgensen L.N. Cost-benefit analysis of prophylaxis against DVT in surgery. Semin. Thromb. Hemost. 17(Suppl. 3):1991;280-283.
34. Hull R.D., Raskob G.E., Pineo G.F., Feldstein W., Rosenbloom D., Gafni A.et al. Subcutaneous low-molecular-weight-heparin vs. warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. Arch. Intern. Med. 157:1997;298-303.
35. Krotenberg R., Adler U., Pomeranz B., Miller J.D., Russell M.W. Dalteparin vs. enoxaparin as prophylaxis for deep-vein thrombosis after total hip or knee arthroplasty: a retrospective analysis. Am. J. Phys. Med. Rehabil. 80(12):2001 (Dec.);889-895.
36. Levin L.A., Bergqvist D. Cost effectiveness of desirudin compared with a LMWH in the prevention of DVT after total hip replacement surgery. PharmacoEconomics. 19:2001;589-597.
37. Levin L.A., Bergqvist H.M. Economic evaluation of desiruding vs. heparin in DVT prevention after hip replacement surgery. PharmacoEconomics. 13:1998;111-118.
38. Lloyd A., Aitken J.A., Hoffmeyer U.K.O., Kelso E.J., Wakerly E.C., Barber N.D. Economic evaluation of the use of nadroparin calcium in the prophylaxis of deep vein thrombosis and pulmonary embolism in surgical patients in Italy. PharmacoEconomics. 12(4):1997;475-485.
39. Lamy A., Wang X., Kent R., Smith K.M., Gafni A. Economic evaluation of the MEDENOX trial: a Canadian perspective. Medical Patients with Enoxaparin. Can. Respir. J. 9(3):2002 (May-Jun);169-177.
40. Marchetti M., Pistorio A., Barone M., Serafini S., Barosi G. Low-molecular-weight heparin versus warfarin for secondary prophylaxis of venous thromboembolism: a cost-effectiveness study. Am. J. Med. 111:2001;130-139.
41. Mamdani M.M., Weingarten C.M., Stevenson J.G. Thromboembolic prophylaxis in moderate-risk patients undergoing elective abdominal surgery: decision and cost-effectiveness analyses. Pharmacotherapy. 16(6):1996;1111-1127.
42. Maxwell R.A., Chavarria-Aguilar M., Cockerham W.T., Lewis P.L., Barker D.E., Durham R.M.et al. Routine prophylactic vena cava filtration is not indicated after acute spinal cord injury. J. Trauma. 52(5):2002 (May);902-906.
43. Maxwell L., Myers E.R., Clarke-Pearson D.L. Cost-effectiveness of deep vein thromboembolism prophylaxis in gynecologic oncology surgery. Obstet. Gynecol. 95(2):2000;206-214.
44. Menzin J., Colditz G.A., Regan M.M., Richner R.E., Oster G. Cost-effectiveness of enoxaparin vs. low-dose warfarin in the prevention of DVT after total hip replacement surgery. Arch. Intern. Med. 155:1995;757-764.
45. Menzin J., Richner R., Huse D., Colditz G.A., Oster O. Prevention of deep-vein thrombosis following total hip replacement surgery with enoxaparin versus unfractunated heparin: a pharmacoeconomic evaluation. Ann. Pharmacother. 28:1994;271-275.
46. O'Brien B., Anderson D.R., Goree R. Cost-effectiveness of enoxaparin versus warfarin prophylaxis against DVT after total hip replacement. Can. Med. Assoc. J. 150(7):1994;1083-1090.
47. Sarasin F.P., Bounameaux H. Cost-effectiveness of prophylactic anticoagulation prolonged after hospital discharge following general surgery. Arch. Surg. 131:1996;694-697.
48. Sarasin F.P., Bounameaux H. Out of hospital antithrombotic prophylaxis after total hip replacement: low-molecular-weight heparin, warfarin, aspirin or nothing? A cost-effectiveness analysis. Thromb. Haemost. 87(4):2002 (Apr.);586-592.
49. Shorr A.F., Ramage A.S. Enoxaparin for thromboprophylaxis after major trauma: potential cost implications. Crit. Care Med. 29(3):2001;1659-1666.
50. Szucs R.D., Schramm W. The cost-effectiveness of low-molecular-weight heparin vs. unfractionated heparin in general and orthopaedic surgery: an analysis for the German Health Care System. Pharmacol. Res. 40(1):1999;83-89.
51. Wade W.E., Chisholm M.A. Venous thrombosis after acute spinal cord injury. Cost analysis of phrophylaxis guidelines. Am. J. Phys. Med. Rehabil. 79(6):2000;504-508.
52. Wade W.E., Spruill W.J. Cost comparison of tinzaparin versus enoxaparin as deep venous thrombosis prophylaxis in spinal cord injury: preliminary data. Blood Coagul. Fibrinolysis. 12(8):2001 (Dec.);619-625.
53. Brewer D. Should low-molecular-weight heparins replace unfractionated heparin as the agent of choice for adults with deep vein thrombosis. J. Fam. Pract. 47(3):1998;185-192.
54. de Lissovoy G. Economic issues in the treatment and prevention of deep vein thrombosis from a managed care perspective. Am. J. Manag. Care. 7:2001;S535-S538. [discussion S538-S544].
55. Matzsch T. Thromboprophylaxis with low-molecular-weight heparin: economic considerations. Haemostasis. 30(Suppl. 2):2000;141-145.
56. Perry D.J. Treating venous thromboembolism: enoxaparin. Hosp. Med. 62:2001 (Dec.);757-764.
57. Seo P., Locke C.F.S. Current and potential uses of low molecular weight heparin: a review and an economic analysis. Am. J. Manag. Care. 6:2000;498-506.
58. Vichiendilokkul A. Breaking out of the silo: one health system's experience. Am. J. Health Syst. Pharm. 59:2002 (Oct. 15);S15-S17.
59. Anthonisen N.R. Some answers, some questions. Can. Respir. J. 9:2002;155-156.
60. Koopman M.M.W. Low-molecular-weight heparins in the treatment of venous thromboembolism. Ann. Intern. Med. 128:1998;1037-1039.
61. Weinstein M.C. High-priced technology can be good value for money. Ann. Intern. Med. 130(10):1999;857-858.
62. Balen R.M., Marra C.A., Zed P.J., Cohen M., Frighetto L. Cost-effectiveness analysis of enoxaparin versus unfractionated heparin for acute coronary syndromes. A Canadian hospital perspective. PharmacoEconomics. 16:1999;533-542.
63. Detournay B., Juet X., Fagnaini F., Montalescot G. Economic evaluation of enoxaparin sodium versus heparin in unstable angina. A French sub-study of the ESSENCE trial. PharmacoEconomics. 18(1):2000;83-89.
64. Gonzalez E.R. Low-molecular-weight heparins for acute coronary syndromes: an emergency perspective. Pharmacotherapy. 19:1999;155S-160S.
65. Malhotra S., Grover A., Verma N.K., Bhargava V.K. A study of drug utilization and cost of treatment in patients hospitalized with unstable angina. Eur. J. Clin. Pharmacol. 56(9):2000;755-761.
66. Mark D. When innovative therapies make economic sense: economic analysis of enoxaparin versus unfractionated heparin in the ESSENCE trial - an overview. Efficacy and safety of subcutaneous in non-Q wave coronary events. Can. J. Cardiol. 14:1998;24E-27E.
67. Murray R.D., Deitcher S.R., Shah A., Jasper S.J., Bashir M., Grimm R.A. et al. Potential clinical efficacy and cost benefit of a transesophageal echocardiography-guided low molecular weight heparin approach to antithrombotic therapy in patients undergoing immediate cardioversion from atrial fibrillation. J. Am. Soc. Echocardiogr. 14(3):2001;200-208.
68. Murray R.D., Shah A., Jasper S.E., Goodman A., Keitcher S.R., Katz W.E. et al. Transesophageal echocardiography guided enoxaprin antithrombotic strategy for cardioversion of atrial fibrillation: the ACUTE II pilot study. Am. Heart J. 139(6):2000;1-7.
69. O'Brien B.J., Willan A., Blackhouse G., Goeree R., Cohen M., Goodman S. Will the use of low-molecular-weight heparin (enoxaparin) in patients with acute coronary syndrome save costs in Canada? Am. Heart J. 139(3):2000;423-429.
70. Spinler S.A. Clinical trials of low-molecular-weight heparins in cardiology. Pharmacotherapy. 19:1999;147S-154S.
71. Spinler S.A., Nawarskas J.J. Low-molecular-weight heparins for acute coronary syndromes. Ann. Pharmacother. 32(1):1998;103-110.
72. Turpie A.G. Low-molecular-weight heparins in acute unstable coronary artery disease - an update. Haemostasis. 29:1999;72-75.
73. Bergqvist D., Matzsch T. Cost-effectiveness of the prevention of postoperative thromboembolism. Orthopade. 22(2):1993;271-275.
74. Frank D., Blattler W. Comparison of ambulatory and inpatient treatment of acute deep venous thrombosis of the leg: subjective and economic aspects. Schweiz. Med. Wochenschr. 128(36):1998;1328-1333.
75. Korin J.D., Sanchez J.C. Avalos Prophylaxis of venous thrombosis. Medicina. 56(3):1996;299-307.
76. Levesque H., Cailleax N., Vasse D., Gegallicier B., Moore N., Borg J.Y. et al. Evaluation of hospital cost of six days of treatment of deep vein thrombosis. Comparison of subcutaneous nadroparin and intravenouse heparin in 40 patients. Therpaie. 49(2):1994;101-105.
77. Osterkorn D., Schramm W., Szucs T. Health care economics evaluation of inpatient treatment of venous thrombosis with unfractionated heparin versus subcutaneous low molecular weight heparin at home. Med. Klin. 91(9):1996;607-609.
78. Hull R.D., Pineo G.F., Raskob G.E. The economic impact of treating deep vein thrombosis with low-molecular-weight heparin: outcome of therapy and health economy aspects. Haemostasis. 28(Suppl. 3):1998;8-16.
79. Van de Belt A.G.M., Bossuyt P.M.M., Prins M.H., Gallus A.S., Buller H.R. Replacing inpatient care by outpatient care in the treatment of deep vein thrombosis - an economic evaluation. Thromb. Haemost. 79:1998;259-263.
80. Boccalon H., Elias A., Chale J.J., Cadene A., Gabriel O. Clinical outcome and cost of hospital vs. home treatment of proximal deep vein thrombosis with a low-molecular-weight heparin. Arch. Intern. Med. 160:2000;1769-1773.
81. Drummond M.F., O'Brien B. Methods for the economic evaluation of health care programmes. 2nd ed. 1997;Oxford Univ. Press, Oxford.
82. Friedberg M., Saffran B., Stinson T.J., Nelson W., Bennett C.L. Evaluation of conflict of interest in economic analyses of new drugs in oncology. JAMA. 282(15):1999;1453-1456.